BRAF mutations conferring resistance to BRAF inhibitors

Details for Australian Patent Application No. 2011221227 (hide)

Owner Dana-Farber Cancer Institute, Inc.

Inventors Garraway, Levi; Emery, Caroline

Agent Spruson & Ferguson

Pub. Number AU-A-2011221227

PCT Pub. Number WO2011/106298

Priority 61/308,275 25.02.10 US

Filing date 22 February 2011

Wipo publication date 1 September 2011

International Classifications

A61K 31/4184

C12N 9/12 Enzymes, e.g. ligases (6.) - transferring phosphorus containing groups, e.g. kinases (2.7)

Event Publications

23 August 2012 PCT application entered the National Phase

  PCT publication WO2011/106298 Priority application(s): WO2011/106298

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011221229-Anti-angiogenesis therapy for the treatment of ovarian cancer

2011221226-Compositions and methods for the diagnosis and treatment of tumor